查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1776752

2032 年液態切片市場預測：按產品類型、生物標記類型、樣本類型、技術、應用、最終用戶和地區進行的全球分析

Liquid Biopsy Market Forecasts to 2032 - Global Analysis By Product Type (Assay Kits & Reagents, Instruments, Services, and Other Product Types), Biomarker Type, Sample Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球液態切片市場預計在 2025 年達到 134.4702 億美元，預計到 2032 年將達到 326.2851 億美元，預測期內的複合年成長率為 13.5%。

液態切片是一種非侵入性診斷技術，透過分析血液和尿液等體液中存在的生物標記（例如循環腫瘤DNA (ctDNA)、RNA和外泌體）來檢測癌症和其他疾病。液態切片可以即時洞察疾病進展，從而實現早期發現、監測治療效果和檢測復發。液態切片提供了一種比傳統組織切片檢查更安全、更快捷的替代方案，可增強患者照護並制定個人化治療策略。

根據國際癌症研究機構（IARC）的數據，預計2023年全球新增癌症病例將超過2,070萬例。

個人化醫療日益受到偏好

個人化醫療的日益興起是液態切片市場擴張的主要催化劑。隨著腫瘤治療日益個人化，臨床醫生越來越依賴液體切片檢查等微創工具來指南治療決策。這些檢測能夠即時監測腫瘤動態，幫助醫師根據個別分子譜制定個人化治療方法。透過循環生物標記檢測可操作突變的能力，支持標靶治療的應用，並改善患者預後。精準診斷需求的不斷成長，正在加速液態切片在研究和臨床領域的應用。

有限的臨床檢驗

許多液態切片檢測，尤其是那些用於檢測早期癌症或罕見突變的檢測，缺乏全面、大規模的臨床試驗來確認其敏感性、特異性和整體可靠性。如果沒有強力的檢驗，醫療保健提供者可能會猶豫是否將這些檢測用於診斷、治療計劃和監測等重要決策。這種不確定性也會影響監理機關的核准和報銷，進一步延緩市場滲透。為了獲得更廣泛的認可，需要進行更多縱向研究和同儕審查證據，以確立其在不同患者群體中的臨床效用。

基因組學和次世代定序儀（NGS）的進展

NGS技術能夠高通量、高精度且經濟高效地分析血液檢體中的循環腫瘤DNA (ctDNA)、外泌體和其他生物標記。這些技術進步使得能夠以前所未有的靈敏度和特異性檢測基因突變、拷貝數變異和表觀遺傳變異。隨著NGS越來越普及並逐漸融入臨床工作流程，其早期診斷癌症、監測病情進展和指南個人化治療的能力將會增強。定序速度、數據分析和生物資訊學的持續改進正在進一步加速液態切片在臨床上的應用。

數據解釋的複雜性

液態切片產生的基因組數據日益複雜，帶來了巨大的挑戰。解讀多個基因組合併區分臨床相關突變和良性突變需要高級生物資訊學專業知識。不一致的報告標準和對突變分類缺乏共識可能會給臨床醫生帶來困惑。這種複雜性可能會延遲治療決策或導致治療方法方案不理想。小型實驗室和醫療保健機構可能缺乏有效管理和分析此類數據的基礎設施。如果沒有精簡的解讀工具和標準化的指南，液態切片的潛力可能無法充分利用。

COVID-19的影響：

新冠疫情對液態切片市場產生了雙重影響。起初，診斷延遲和就診次數減少導致癌症篩檢和監測業務暫時下滑。然而，對非侵入性、遠端檢測解決方案的需求使液體切片檢查重新成為人們關注的焦點。隨著醫療體系的調整，液體切片檢查已成為比組織切片檢查更安全的替代方案，尤其對於免疫力缺乏的患者。疫情過後，人們對早期檢測和即時監測的認知不斷提高，加速了市場應用。

預計設備部分將成為預測期內最大的部分

預計儀器儀表領域將在預測期內佔據最大的市場佔有率，因為NGS系統、數位PCR和微流體設備等平台在實現精準的生物標記檢測方面發揮關鍵作用。這些儀器儀表構成了液態切片工作流程的支柱，支持研究和臨床應用。定序速度、通量和自動化的持續創新正在提高檢測的效率和擴充性。隨著對高靈敏度診斷的需求不斷成長，對先進設備的投資預計也將增加。

專科診所部門預計在預測期內實現最高複合年成長率

預計專科診所細分市場將在預測期內實現最高成長率。這些診所擴大採用液態切片進行癌症篩檢、治療方法選擇和復發監測。其集中的專業知識和精簡的工作流程使其成為高級診斷的理想環境。個人化醫療意識的不斷增強，促使患者前往專科中心尋求客製化治療。此外，診斷公司與專科診所之間的合作也擴大了尖端偵測的可近性。

比最大的地區

由於癌症發病率上升、醫療基礎設施擴張以及政府加大對精準醫療的投資，預計亞太地區將在預測期內佔據最大市場佔有率。中國、印度和日本等國家正迅速普及包括液態切片在內的先進診斷技術。本土企業也紛紛進入市場，提供符合當地需求的經濟高效的解決方案。官民合作關係和有利的監管改革正在進一步加速市場滲透。

複合年成長率最高的地區：

北美受惠於成熟的醫療保健體系、強大的研發生態系統以及基因組技術的早期應用。基於液態切片的伴隨診斷的監管核准不斷增加，提升了臨床可靠性。此外，對非侵入性癌症篩檢和監測的需求不斷成長，刺激了檢測量的增加。生物技術公司、學術機構和醫療保健提供者之間的策略聯盟正在推動創新。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球液態切片市場（依產品類型）

  • 檢測套件和試劑
  • 裝置
  • 服務
    • 臨床檢測服務
    • 生物標記發現服務
    • 客製化檢測開發
    • 數據分析與生物資訊軟體
  • 其他產品類型

6. 全球液態切片市場（依生物標記類型）

  • 循環性腫瘤細胞（CTC）
  • 循環腫瘤DNA（ctDNA）
  • 外泌體和細胞外囊泡
  • 遊離DNA（cfDNA）
  • 遊離RNA
  • 循環蛋白
  • 其他生物標記類型

7. 全球液態切片市場（依樣本類型）

  • 血
  • 唾液
  • 尿
  • 糞便樣本採集
  • 其他體液

8. 全球液態切片市場（按技術）

  • 次世代定序（NGS）
  • 珠子、乳劑、放大、磁性（BEAMing）
  • 聚合酵素鏈鎖反應（PCR）
  • 數位液滴PCR（ddPCR）
  • 其他技術

9. 全球液態切片市場（按應用）

  • 癌症應用
    • 治療方法方案
    • 治療監測
    • 復發監測
    • 早期癌症篩檢
    • 預後
  • 非癌症用途
    • 非侵入性產前檢測（NIPT）
    • 器官移植
    • 傳染病檢查
    • 生殖健康
  • 其他用途

第 10 章全球液態切片市場（按最終用戶）

  • 醫院和醫生檢查室
  • 診斷實驗室
  • 學術研究機構
  • 生物製藥和生物技術公司
  • 參考實驗室
  • 專科診所
  • 其他最終用戶

第 11 章全球液態切片市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • F. Hoffmann-La Roche Ltd.
  • Menarini Silicon Biosystems
  • Guardant Health Inc.
  • Freenome Holdings, Inc.
  • Illumina Inc.
  • Biocept, Inc.
  • Thermo Fisher Scientific Inc.
  • ANGLE plc
  • Exact Sciences Corporation
  • Caris Life Sciences
  • Natera Inc.
  • NeoGenomics Laboratories
  • QIAGEN NV
  • Lucence Health Inc.
  • Bio-Rad Laboratories Inc.
  • Foundation Medicine, Inc.
  • Epigenomics AG
  • Johnson & Johnson Services Inc.
  • Myriad Genetics, Inc.
  • Sysmex Corporation
Product Code: SMRC30083

According to Stratistics MRC, the Global Liquid Biopsy Market is accounted for $13447.02 million in 2025 and is expected to reach $32628.51 million by 2032 growing at a CAGR of 13.5% during the forecast period. Liquid biopsy is a non-invasive diagnostic technique that detects cancer and other diseases by analyzing biomarkers such as circulating tumor DNA (ctDNA), RNA, or exosomes present in body fluids like blood or urine. It offers a real-time snapshot of disease progression, enabling early detection, monitoring of treatment response, and detection of recurrence. Liquid biopsy provides a safer, quicker alternative to traditional tissue biopsies, enhancing patient care and personalized treatment strategies.

According to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases are expected in 2023.

Market Dynamics:

Driver:

Increased preference for personalized medicine

The growing shift toward personalized medicine is a major catalyst for the expansion of the liquid biopsy market. As oncology care becomes more tailored, clinicians increasingly rely on minimally invasive tools like liquid biopsy to guide treatment decisions. These tests enable real-time monitoring of tumor dynamics, helping physicians adjust therapies based on individual molecular profiles. The ability to detect actionable mutations through circulating biomarkers supports the use of targeted therapies, improving patient outcomes. This rising demand for precision diagnostics is accelerating the adoption of liquid biopsy across research and clinical settings.

Restraint:

Limited clinical validation

Many liquid biopsy tests, particularly those detecting early-stage cancers or rare mutations, lack comprehensive, large-scale clinical trials to confirm their sensitivity, specificity, and overall reliability. Without robust validation, healthcare providers may hesitate to trust these tests for critical decisions such as diagnosis, treatment planning, or monitoring. This uncertainty also impacts regulatory approvals and insurance reimbursements, further delaying market penetration. To gain broader acceptance, more longitudinal studies and peer-reviewed evidence are essential to establish clinical utility across diverse patient populations.

Opportunity:

Advancements in genomics and next-generation sequencing (NGS)

NGS technologies enable high-throughput, accurate, and cost-effective analysis of circulating tumor DNA (ctDNA), exosomes, and other biomarkers from blood samples. These innovations allow for the detection of genetic mutations, copy number variations, and epigenetic changes with unprecedented sensitivity and specificity. As NGS becomes more accessible and integrated into clinical workflows, it enhances the ability to diagnose cancer early, monitor disease progression, and guide personalized treatment. Continuous improvements in sequencing speed, data analytics, and bioinformatics are further accelerating the clinical adoption of liquid biopsy.

Threat:

Complexity in data interpretation

The increasing complexity of genomic data generated by liquid biopsy tests poses a significant challenge. Interpreting multi-gene panels and distinguishing clinically relevant mutations from benign variants requires advanced bioinformatics expertise. Inconsistent reporting standards and lack of consensus on variant classification can lead to confusion among clinicians. This complexity may delay treatment decisions or result in suboptimal therapy selection. Smaller labs and healthcare providers may lack the infrastructure to manage and analyze such data effectively. Without streamlined interpretation tools and standardized guidelines, the full potential of liquid biopsy may remain underutilized.

Covid-19 Impact:

The COVID-19 pandemic had a dual impact on the liquid biopsy market. Initially, diagnostic delays and reduced hospital visits led to a temporary decline in cancer screening and monitoring procedures. However, the need for non-invasive, remote-friendly testing solutions brought renewed attention to liquid biopsy. As healthcare systems adapted, liquid biopsy emerged as a safer alternative to tissue biopsies, especially for immunocompromised patients. Post-pandemic, the market witnessed accelerated adoption driven by increased awareness of early detection and real-time monitoring.

The instruments segment is expected to be the largest during the forecast period

The instruments segment is expected to account for the largest market share during the forecast period, due to the critical role of platforms such as NGS systems, digital PCR, and microfluidic devices in enabling accurate biomarker detection. These instruments form the backbone of liquid biopsy workflows, supporting both research and clinical applications. Continuous innovation in sequencing speed, throughput, and automation is enhancing test efficiency and scalability. As demand for high-sensitivity diagnostics grows, investment in advanced instrumentation is expected to rise.

The specialty clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the specialty clinics segment is predicted to witness the highest growth rate. These clinics are increasingly adopting liquid biopsy for cancer screening, therapy selection, and recurrence monitoring. Their focused expertise and streamlined workflows make them ideal settings for implementing advanced diagnostics. As awareness of personalized medicine grows, patients are turning to specialty centers for tailored care. Additionally, partnerships between diagnostic companies and specialty clinics are expanding access to cutting-edge tests.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rising cancer incidence, expanding healthcare infrastructure, and increasing government investment in precision medicine. Countries like China, India, and Japan are witnessing rapid adoption of advanced diagnostics, including liquid biopsy. Local players are also entering the market with cost-effective solutions tailored to regional needs. Public-private partnerships and favorable regulatory reforms are further accelerating market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to the region benefits from a well-established healthcare system, strong R&D ecosystem, and early adoption of genomic technologies. Regulatory approvals for liquid biopsy-based companion diagnostics are increasing, boosting clinical confidence. Additionally, rising demand for non-invasive cancer screening and monitoring is fueling test volumes. Strategic collaborations between biotech firms, academic institutions, and healthcare providers are driving innovation.

Key players in the market

Some of the key players in Liquid Biopsy Market include F. Hoffmann-La Roche Ltd., Menarini Silicon Biosystems, Guardant Health Inc., Freenome Holdings, Inc., Illumina Inc., Biocept, Inc., Thermo Fisher Scientific Inc., ANGLE plc, Exact Sciences Corporation, Caris Life Sciences, Natera Inc., NeoGenomics Laboratories, QIAGEN N.V., Lucence Health Inc., Bio-Rad Laboratories Inc., Foundation Medicine, Inc., Epigenomics AG, Johnson & Johnson Services Inc., Myriad Genetics, Inc., and Sysmex Corporation.

Key Developments:

In May 2025, Roche announced a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche's recently unveiled next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology. This collaboration will focus on harnessing the power of the SBX technology to transform clinical genomics and biomedical discovery. It will also aim to establish the SBX technology as a routine offering for fast, scalable sequencing for Broad Clinical Lab's research community.

In July 2022, Menarini Silicon Biosystems Inc, announced at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo that they have entered into a commercial agreement for the exclusive distribution of the CHORUS TRIO immunometric assay system in the United States of America.

Product Types Covered:

  • Assay Kits & Reagents
  • Instruments
  • Services
  • Other Product Types

Biomarker Types Covered:

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Exosomes and Extracellular Vesicles
  • Cell-Free DNA (cfDNA)
  • Cell-Free RNA (cfRNA)
  • Circulating Proteins
  • Other Biomarker Types

Sample Types Covered:

  • Blood
  • Saliva
  • Urine
  • Fecal-Based Sampling
  • Other Body Fluids

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Beads, Emulsion, Amplification, and Magnetics (BEAMing)
  • Polymerase Chain Reaction (PCR)
  • Digital Droplet PCR (ddPCR)
  • Other Technologies

Applications Covered:

  • Cancer Applications
  • Non-Cancer Applications
  • Other Applications

End Users Covered:

  • Hospitals and Physician Laboratories
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Biopharmaceutical and Biotechnology Companies
  • Reference Laboratories
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Liquid Biopsy Market, By Product Type

  • 5.1 Introduction
  • 5.2 Assay Kits & Reagents
  • 5.3 Instruments
  • 5.4 Services
    • 5.4.1 Clinical Testing Services
    • 5.4.2 Biomarker Discovery Services
    • 5.4.3 Customized Assay Development
    • 5.4.4 Data Analysis and Bioinformatics Software
  • 5.5 Other Product Types

6 Global Liquid Biopsy Market, By Biomarker Type

  • 6.1 Introduction
  • 6.2 Circulating Tumor Cells (CTCs)
  • 6.3 Circulating Tumor DNA (ctDNA)
  • 6.4 Exosomes and Extracellular Vesicles
  • 6.5 Cell-Free DNA (cfDNA)
  • 6.6 Cell-Free RNA (cfRNA)
  • 6.7 Circulating Proteins
  • 6.8 Other Biomarker Types

7 Global Liquid Biopsy Market, By Sample Type

  • 7.1 Introduction
  • 7.2 Blood
  • 7.3 Saliva
  • 7.4 Urine
  • 7.5 Fecal-Based Sampling
  • 7.6 Other Body Fluids

8 Global Liquid Biopsy Market, By Technology

  • 8.1 Introduction
  • 8.2 Next-Generation Sequencing (NGS)
  • 8.3 Beads, Emulsion, Amplification, and Magnetics (BEAMing)
  • 8.4 Polymerase Chain Reaction (PCR)
  • 8.5 Digital Droplet PCR (ddPCR)
  • 8.6 Other Technologies

9 Global Liquid Biopsy Market, By Application

  • 9.1 Introduction
  • 9.2 Cancer Applications
    • 9.2.1 Therapy Selection
    • 9.2.2 Treatment Monitoring
    • 9.2.3 Recurrence Monitoring
    • 9.2.4 Early Cancer Screening
    • 9.2.5 Prognosis
  • 9.3 Non-Cancer Applications
    • 9.3.1 Non-Invasive Prenatal Testing (NIPT)
    • 9.3.2 Organ Transplantation
    • 9.3.3 Infectious Disease Testing
    • 9.3.4 Reproductive Health
  • 9.4 Other Applications

10 Global Liquid Biopsy Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals and Physician Laboratories
  • 10.3 Diagnostic Laboratories
  • 10.4 Academic and Research Institutes
  • 10.5 Biopharmaceutical and Biotechnology Companies
  • 10.6 Reference Laboratories
  • 10.7 Specialty Clinics
  • 10.8 Other End Users

11 Global Liquid Biopsy Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 F. Hoffmann-La Roche Ltd.
  • 13.2 Menarini Silicon Biosystems
  • 13.3 Guardant Health Inc.
  • 13.4 Freenome Holdings, Inc.
  • 13.5 Illumina Inc.
  • 13.6 Biocept, Inc.
  • 13.7 Thermo Fisher Scientific Inc.
  • 13.8 ANGLE plc
  • 13.9 Exact Sciences Corporation
  • 13.10 Caris Life Sciences
  • 13.11 Natera Inc.
  • 13.12 NeoGenomics Laboratories
  • 13.13 QIAGEN N.V.
  • 13.14 Lucence Health Inc.
  • 13.15 Bio-Rad Laboratories Inc.
  • 13.16 Foundation Medicine, Inc.
  • 13.17 Epigenomics AG
  • 13.18 Johnson & Johnson Services Inc.
  • 13.19 Myriad Genetics, Inc.
  • 13.20 Sysmex Corporation

List of Tables

  • Table 1 Global Liquid Biopsy Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Liquid Biopsy Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Liquid Biopsy Market Outlook, By Assay Kits & Reagents (2024-2032) ($MN)
  • Table 4 Global Liquid Biopsy Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 5 Global Liquid Biopsy Market Outlook, By Services (2024-2032) ($MN)
  • Table 6 Global Liquid Biopsy Market Outlook, By Clinical Testing Services (2024-2032) ($MN)
  • Table 7 Global Liquid Biopsy Market Outlook, By Biomarker Discovery Services (2024-2032) ($MN)
  • Table 8 Global Liquid Biopsy Market Outlook, By Customized Assay Development (2024-2032) ($MN)
  • Table 9 Global Liquid Biopsy Market Outlook, By Data Analysis and Bioinformatics Software (2024-2032) ($MN)
  • Table 10 Global Liquid Biopsy Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 11 Global Liquid Biopsy Market Outlook, By Biomarker Type (2024-2032) ($MN)
  • Table 12 Global Liquid Biopsy Market Outlook, By Circulating Tumor Cells (CTCs) (2024-2032) ($MN)
  • Table 13 Global Liquid Biopsy Market Outlook, By Circulating Tumor DNA (ctDNA) (2024-2032) ($MN)
  • Table 14 Global Liquid Biopsy Market Outlook, By Exosomes and Extracellular Vesicles (2024-2032) ($MN)
  • Table 15 Global Liquid Biopsy Market Outlook, By Cell-Free DNA (cfDNA) (2024-2032) ($MN)
  • Table 16 Global Liquid Biopsy Market Outlook, By Cell-Free RNA (cfRNA) (2024-2032) ($MN)
  • Table 17 Global Liquid Biopsy Market Outlook, By Circulating Proteins (2024-2032) ($MN)
  • Table 18 Global Liquid Biopsy Market Outlook, By Other Biomarker Types (2024-2032) ($MN)
  • Table 19 Global Liquid Biopsy Market Outlook, By Sample Type (2024-2032) ($MN)
  • Table 20 Global Liquid Biopsy Market Outlook, By Blood (2024-2032) ($MN)
  • Table 21 Global Liquid Biopsy Market Outlook, By Saliva (2024-2032) ($MN)
  • Table 22 Global Liquid Biopsy Market Outlook, By Urine (2024-2032) ($MN)
  • Table 23 Global Liquid Biopsy Market Outlook, By Fecal-Based Sampling (2024-2032) ($MN)
  • Table 24 Global Liquid Biopsy Market Outlook, By Other Body Fluids (2024-2032) ($MN)
  • Table 25 Global Liquid Biopsy Market Outlook, By Technology (2024-2032) ($MN)
  • Table 26 Global Liquid Biopsy Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 27 Global Liquid Biopsy Market Outlook, By Beads, Emulsion, Amplification, and Magnetics (BEAMing) (2024-2032) ($MN)
  • Table 28 Global Liquid Biopsy Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 29 Global Liquid Biopsy Market Outlook, By Digital Droplet PCR (ddPCR) (2024-2032) ($MN)
  • Table 30 Global Liquid Biopsy Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 31 Global Liquid Biopsy Market Outlook, By Application (2024-2032) ($MN)
  • Table 32 Global Liquid Biopsy Market Outlook, By Cancer Applications (2024-2032) ($MN)
  • Table 33 Global Liquid Biopsy Market Outlook, By Therapy Selection (2024-2032) ($MN)
  • Table 34 Global Liquid Biopsy Market Outlook, By Treatment Monitoring (2024-2032) ($MN)
  • Table 35 Global Liquid Biopsy Market Outlook, By Recurrence Monitoring (2024-2032) ($MN)
  • Table 36 Global Liquid Biopsy Market Outlook, By Early Cancer Screening (2024-2032) ($MN)
  • Table 37 Global Liquid Biopsy Market Outlook, By Prognosis (2024-2032) ($MN)
  • Table 38 Global Liquid Biopsy Market Outlook, By Non-Cancer Applications (2024-2032) ($MN)
  • Table 39 Global Liquid Biopsy Market Outlook, By Non-Invasive Prenatal Testing (NIPT) (2024-2032) ($MN)
  • Table 40 Global Liquid Biopsy Market Outlook, By Organ Transplantation (2024-2032) ($MN)
  • Table 41 Global Liquid Biopsy Market Outlook, By Infectious Disease Testing (2024-2032) ($MN)
  • Table 42 Global Liquid Biopsy Market Outlook, By Reproductive Health (2024-2032) ($MN)
  • Table 43 Global Liquid Biopsy Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 44 Global Liquid Biopsy Market Outlook, By End User (2024-2032) ($MN)
  • Table 45 Global Liquid Biopsy Market Outlook, By Hospitals and Physician Laboratories (2024-2032) ($MN)
  • Table 46 Global Liquid Biopsy Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 47 Global Liquid Biopsy Market Outlook, By Academic and Research Institutes (2024-2032) ($MN)
  • Table 48 Global Liquid Biopsy Market Outlook, By Biopharmaceutical and Biotechnology Companies (2024-2032) ($MN)
  • Table 49 Global Liquid Biopsy Market Outlook, By Reference Laboratories (2024-2032) ($MN)
  • Table 50 Global Liquid Biopsy Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 51 Global Liquid Biopsy Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.